miss organ revenu growth expect reduc
fy guidanc possibl result even wors appear surfac japan
pull forward guid particularli discourag extra sell day y/i new
instrument suppos help expect share today
price-to-earnings await detail call
constant currenc revenu growth y/i miss expect overal
revenu forecast consensu
rel forecast water divis organ growth wors expect
y/i organ vs y/i forecast ta come better expect
y/i organ vs y/i forecast end market perform except
well pharma grow y/i cc industrial/appli flat y/i cc academic/gov
y/i cc
geographi america weak y/i cc manag call late
quarter weak us tmo/dhr call europ revenu grew y/i
cc asia grew y/i cc worth note asia growth could aid pull
forward japan revenu link japan repres total sale
gross margin y/i forecast despit lower instrument
mix oper margin y/i came expect
driven lower opex y/i ep y/i came
forecast line consensu exclud compani share repurchas program ep
would declin y/i
constant currenc revenu growth expect approxim y/i
y/i previous well origin guidanc full year ep
expect approxim midpoint
guidanc also expect constant currenc growth guid
y/i ep guid vs consensu particularli discourag
given one extra sell day y/i manag previous expect
new instrument launch begin contribut result
amidst string quarterli organ revenu growth miss past year
arguabl amongst worst especi factor weak guidanc
water divis instrument revenu continu weak like msd y/i
recur revenu growth continu track histor trend year trend
consist move wrong direct obviou sign new product
materi improv result growth expect approxim y/i despit
benefit one extra sell day y/i could y/i tailwind multipl new
pleas see page report import disclosur
instrument launch previous expect begin contribut result clear sign
within guidanc
key compon long thesi stock predic favor comparison
new product catalyz return msd y/i revenu growth new product
benefit difficult assum benefit materi
expect stock today repres around
price-to-earnings could see stock even although still strong returns/cash flow
compani result thomson eikon cowen compani
cowen vs consensu mm except cc cc previous cc growthgross re-affirmed oper revenu metric mm except statement mm except currenc per count ep came forecast line consensu underli driver ep growth quarter weak growth driven primarili via buyback opex cut divis revenu came forecast constant currenc revenu growth y/i expect biggest sourc continu weak appear via instrument estim least lsd possibl y/i cc manag call late quarter weak america someth larg cap compani univers call date ta revenu came forecast constant currenc growth y/i expect result like solid across instrument servic encourag result context industrial/cycl concern streetaccount consensu y/i cc revenu came forecast consensu constant currenc revenu growth came consensu expect end market pharma grew y/i cc industri flat y/i acc/gov declin y/i cc geographi asia grew y/i cc europ flat y/i america declin y/i cc manag call late quarter weak america consist larg cap peer commentari date weak like specif gross margin came forecast despit lower instrument revenu mix came forecast sale sg came forecast sale oper margin came forecast driven entir opex cut revenu gross margin well expect encourag oper quarter slightli forecast cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk upsid includ limit recoveri macroeconom condit
increas client budget demand lc/m instrument consum better
expect product innov associ revenu contribut share gain risk
downsid includ limit macroeconom deterior current
level inabl execut integr eros market share price due
competit inabl deliv incremental/decrement margin target value-
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen cross-asset research due natur fix incom market issuer debt secur issuer discuss cowen cross-asset research report
assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon analysi reflect
analyst opinion date report expect continu analysi addit report relat issuer debt secur issuer
time time cowen cross-asset research analyst provid invest recommend secur subject report recommend intend
time date public within paramet specifi individu report cowen cross-asset research invest recommend made
strictli case-by-cas basi recommend provid part overarch rate system set consist appli benchmark view express
cross-asset research report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc octob et dissemin octob et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
